TWD
KROS icon

True Wealth Design’s Keros Therapeutics KROS Stock Holding History

True Wealth Design’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71K Buy
160
+145
+967% +$1.61K ﹤0.01% 1754
2026
Q1 		$166 Sell
15
-57
-79% -$880 ﹤0.01% 2368
2025
Q4 		$1.47K Buy
72
+53
+279% +$930 ﹤0.01% 1567
2025
Q3 		$301 Buy
19
+13
+217% +$192 ﹤0.01% 2184
2025
Q2 		$81 Buy
6
+3
+100% +$41 ﹤0.01% 2291
2025
Q1 		$31 Buy
+3
New +$35 ﹤0.01% 2503

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

True Wealth Design's KROS Position: Q2 2026 in Review

True Wealth Design increased its Keros Therapeutics (KROS) stake by 967% in Q2 2026, buying an estimated $1.61K and bringing the position to 160 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1754.

True Wealth Design first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • True Wealth Design held 160 shares of Keros Therapeutics worth $1.71K as of Q2 2026.
  • True Wealth Design bought 145 Keros Therapeutics shares in Q2 2026, an estimated $1.61K.
  • Keros Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1754 holding.
  • True Wealth Design first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.